相关实验视频
Updated: May 28, 2025
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
366
在阿尔茨海默病的背景下,专注于数字认知评估的重点小组
Sophie M van der Landen1,2, Rosanne L van den Berg1,2,3, Matthijs J Keijzer1,2,4
1Alzheimer Center Amsterdam, Neurology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Digital health
|February 13, 2025
概括
数字认知评估 (DCAs) 有助于早期发现阿尔茨海默病 (AD). 用户友好和个性化的方法是克服障碍和增加这些数字工具用于大脑健康的采用的关键.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 数字健康数字健康
背景情况:
- 数字认知评估 (DCAs) 显示出早期发现阿尔茨海默病 (AD) 认知衰退的前景.
- 尽管DCAs具有潜力,但其在临床实践中尚未得到广泛应用.
- 了解用户的观点对于成功集成DCAs至关重要.
研究的目的:
- 确定影响老年人和患者采用DCA的促进者和障碍.
- 探索用户对数字认知评估的动机,适用性和特征的看法.
主要方法:
- 五个焦点小组与老年人 (未受损,主观认知衰退,生物标志物确认的AD轻度认知障碍) 和他们的护理人员进行了调查.
- 三个不同的DCA向参与者介绍.
- 来自记录的焦点小组的成绩单使用专题分析进行了分析.
主要成果:
- 出现的关键主题是:测试动机 (平衡早期识别与对痴呆症的恐惧),数字测试适用性 (在家测试的方便性与缺乏个人接触) 和数字测试特征 (强调用户友好性以解决数字无能).
- 影响收养的因素在个体之间有所不同,突出了个性化策略的必要性.
- 用户友好性被认为是克服数字挑战的关键促进因素.
结论:
- 参与者承认DCAs对于认知健康监测的价值.
- 通过量身定制的战略解决个别促进者和障碍,对于促进DCA的实施至关重要.
- 优化用户体验并提供关于好处和风险的清晰沟通可以提高DCA接受度.
相关概念视频
01:30Dementia
92
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
92
01:26Alzheimer's Disease: Overview
432
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
432
01:30Cognitive Development During Adulthood
46
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
46
01:22Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95